— $150 million secured at closing extends cash runway into early 2027 — REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty […]

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 GlobeNewswire May 19, 2025 NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune

(NASDAQ:ANNX), First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barre Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart's Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE,

(NasdaqGM:OCX), New price of $2,753 for the GraftAssureCore(TM) assay increases total addressable market size and margin opportunity Brings pricing in line with existing competitive technology Expands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a

Sydney, Australia, May 19, 2025 (GLOBE NEWSWIRE) — Sydney, Australia–According to the CoinMarketCap Fear and Greed Index, crypto market sentiment in May 2025 remains in the “Extreme Greed” zone, reflecting strong investor appetite for digital assets. With this momentum, cloud mining has become a strategic entry point for both new and experienced crypto investors. Among

(NYSE MKT:AEON),(NYSE MKT:AEON.WS),(NYSE MKT:AEON-WS), IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON's President and Chief Executive Officer, will present a corporate overview

(NASDAQ:CBUS), SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP

(NASDAQ:HUMA), DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq in New

(NYSE:SB),(NYSE:SB-PC),(NYSE:SB-PD), MONACO, May 19, 2025 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today its unaudited financial results for the three-month periods ended March 31, 2025. The Board of Directors (“the Board”) of the Company also declared a cash dividend of $0.05 per share

(NasdaqGM:BIGC), AUSTIN, Texas, May 19, 2025 (GLOBE NEWSWIRE) — BigCommerce Holdings, Inc. (“BigCommerce”) (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands, retailers, manufacturers and distributors, today announced that Chief Financial Officer Daniel Lentz will present and host meetings with institutional investors at the Baird Global Consumer, Technology